Brief: HLS Therapeutics Announces Q3 2024 Financial Results
07/11/2024 13:23
Nov 7 (Reuters) - HLS Therapeutics Inc HLS.TO :
* HLS THERAPEUTICS ANNOUNCES Q3 2024 FINANCIAL RESULTS
* HLS THERAPEUTICS: NAMED JOHN HANNA PERMANENT CFO AND
PROMOTED
BRIAN WALSH TO CHIEF COMMERCIAL OFFICER
* HLS THERAPEUTICS INC: QTRLY LOSS PER SHARE $0.15
* HLS THERAPEUTICS INC: OUTLOOK FY24 REVENUE $56.5-57.2
MILLION
Source text: ID:nCNW6qSwXa
Further company coverage: HLS.TO
((Reuters.Briefs@thomsonreuters.com;))
Recent news on HLS Therapeutics
See all newsCanada Research Roundup: CIBC ,HLS Therapeutics, TD Bank Group
Canada's HLS Therapeutics Q1 revenue rises on Vascepa growth, reaffirms 2026 guidance
Canada's HLS Therapeutics Q4 revenue slightly beats on Vascepa strength
Brief: Esperion Partner announces HLS Therapeutics received approval Of NILEMDO for the reduction of LDL-cholesterol in canadians at risk of cardiovascular disease
Brief: HLS Therapeutics announces Health Canada approval of NILEMDO for the reduction of LDL-Cholesterol in Canadians at risk of cardiovascular disease